ARCT Insider Trading
Insider Ownership Percentage: 16.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,294,510.00
Arcturus Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Arcturus Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Arcturus Therapeutics Share Price & Price History
Current Price: $12.63
Price Change: ▼ Price Decrease of -0.1 (-0.79%)
As of 05/30/2025 05:00 PM ET
Arcturus Therapeutics Insider Trading History
Arcturus Therapeutics Institutional Trading History
Data available starting January 2016
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More on Arcturus Therapeutics
Today's Range
Now: $12.63
52 Week Range
Now: $12.63
Volume
1,003,031 shs
Average Volume
448,762 shs
Market Capitalization
$342.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.36
Who are the company insiders with the largest holdings of Arcturus Therapeutics?
Who are the major institutional investors of Arcturus Therapeutics?
Which major investors are selling Arcturus Therapeutics stock?
Within the last quarter, ARCT stock was sold by these institutional investors:
- Sumitomo Mitsui Trust Group Inc.
- Nikko Asset Management Americas Inc.
- Caption Management LLC
- Jane Street Group LLC
- Woodline Partners LP
- Empire Life Investments Inc.
- Charles Schwab Investment Management Inc.
- Rafferty Asset Management LLC
Which major investors are buying Arcturus Therapeutics stock?
In the last quarter, ARCT stock was purchased by institutional investors including:
- Millennium Management LLC
- Vestal Point Capital LP
- ARK Investment Management LLC
- Acadian Asset Management LLC
- Vanguard Group Inc.
- Nuveen LLC
- Goldman Sachs Group Inc.
- Dynamic Technology Lab Private Ltd